Spectrum Pharmaceuticals receives notice of a U.S. patent allowance for potential drug fo ADHD

Spectrum Pharmaceuticals has announced that it has received from the U.S. Patent and Trademark Office (USPTO) a Notice of Allowance for its patent application for SPI-339 entitled "Methods for Treating Cognitive/Attention Deficit Disorders Using Tetrahydroindolone Analogues and Derivatives."

This patent, when issued, will protect SPI-339 for use in the treatment of ADHD and other neurological disorders and will not expire until 2021.

"We are happy to receive this notice of allowance on SPI-339," stated Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer and President of Spectrum Pharmaceuticals, Inc. "This patent, when issued, will be a significant addition to our intellectual property portfolio on our Central Nervous System (CNS) compounds and will strengthen our ability to out-license this product for further development and marketing by a partner. In addition to SPI-339, our CNS portfolio includes antipsychotic compounds SPI-376 and SPI-392, all of which are available out-licensing opportunities."

SPI-339 is an orally available small molecule drug that has potential applications for the treatment of attention disorders, memory acquisition and other cognitive functions. Potential applications of SPI-339 include treatment of children and adults with Attention Deficit and Hyperactivity Disorder (ADHD). Although the precise mechanism of action of SPI-339 is not known, it is known to be different from that of the stimulants that are commonly used to treat ADHD.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Thames typical of superbug-breeding rivers, says new study